Journal of Liver Cancer

Seok Hyun Kim

3 Articles

A Case of Extrahepatic Metastasis of Hepatocellular Carcinoma to the Pronator Quadratus Muscle of Right Wrist: Yonng Wook Song, Byung seok Lee, Seok Hyun Kim, Eaum seok Lee, Heon Young Lee; J Liver Cancer. 2015;15(1):41-45. Published online March 31, 2015; DOI: https://doi.org/10.17998/jlc.15.1.41

965 Views
3 Downloads

Abstract PDF: Hepatocellular carcinoma (HCC) is usually associated with chronic liver disease such as liver cirrhosis. Primary HCC lesions and even recurrent intrahepatic lesions can be treated successfully by using variable modalities applicable to intrahepatic lesions. HCC can cause intrahepatic multiple occurrence and extrahepatic metastasis. Extrahepatic metastasis occurs in up to about 60% of patients of HCC, and a major of patients with extrahepatic HCC had late intrahepatic stage of tumor. Themost frequent site of extrahepatic metastasis of HCC was the lung. HCC metastasized to soft tissues was unusually reported. Extrahepatic metastasis of HCC, especially to unusual site, should not be overlooked and must be able to be controlled. We experienced a case that HCC was metastasized to the pronator quadratus muscle of right wrist and chould be removed surgically.

3 Cases of Portal Vein Thrombosis in Hepatocellular Carcinoma and Liver Cirrhosis Treated with Anticoagulation: Byung Moo Ahn, Eaum Seok Lee, Seok Hyun Kim, Byung Seok Lee, Heon Young Lee; J Liver Cancer. 2015;15(1):57-63. Published online March 31, 2015; DOI: https://doi.org/10.17998/jlc.15.1.57

1,299 Views
20 Downloads
1 Citation

Abstract PDF

The reported prevalence of PVT is in the range of 0.6-15.8% in patient with liver cirrhosis or portal hypertension. If the patient has hepatocellular carcinoma, thrombus is likely to be malignant thrombus. Malignancy, frequently of hepatic origin, is responsible for 21-24% of over all cases. The overall mortality rate of chronic PVT has been reported to be less than 10%, but is increased to 26% when associated with hepatocellular carcinoma and cirrhosis. However, no treatment guideline has been established on anticoagulant therapy for PVT in patients with concomitant hepatocellular carcinoma and cirrhosis. Because actually it is not easy to distinguish between malignant thrombus and benign thrombus in clinical aspect, PVT in hepatocellular carcinoma are still debatable whether or not treatment when it diagnosed. We present 3 cases of portal vein thrombosis successfully treated with anticoagulation in hepatocellular carcinoma and liver cirrhosis, and we include a literature review.

Citations

Citations to this article as recorded by

Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients
Ji Min Han, Youngil Koh, Sung Hwan Kim, Sung Yun Suh, Yoon Sook Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Hye Sun Gwak
Medicina.2023; 59(2): 292. CrossRef

A Case of Combined hepatocellular carcinoma and cholangiocarcinoma (CHC) without underlying liver disease.: Jae Hoon Jung, Jung Il Kim, Sun Hyung Kang, Seok Hee Moon, Seok Hyun Kim, Byung Seok Lee, Heon Young Lee, Joon Sik Cho, Kyung Sook Shin, Dae Young Kang, Hyun Mo Kang; Journal of the Korean Liver Cancer Study Group. 2007;7(1):62-65. Published online June 30, 2007

560 Views
1 Download

Abstract PDF: Combined hepatocellular carcinoma and cholangiocarcinoma (CHC) is a rare form of primary liver cancer having features of both hepatocelluar and biliary epithelial differentiation and is related to cirrhosis. Recently, a 64-oldmale who was admitted to our hospital for evaulation of hepatic mass which was detected on ultrasonography. He had no underlying cirrhosis. Based on serologic findings of high alpha-fetoprotein(AFP) level, a preoperative diagnosis of hepatocellular carcinoma was made. A right lobectomy was done. On histologic examination, the resected tumor was shown to consist of two different tissues. On immunohistochemistry, the tumor is postitive for both anti-hepatocyte, CK-7 and CK-19. Finally we confirm combined hepatocellular carcinoma and cholangiocarcinoma (CHC).